Cell therapy scale is where the romance ends

by James ColeScience and Modalities Editor, HMND

Cell therapy keeps getting described like a triumph of biology, and the biology really is extraordinary, but the harder question sits one floor down in the plant, in the courier handoff, and in the database that still has to prove the right cells reached the right patient in the right state. Industrial scale is pressing harder now, with commercial scale manufacturing taking the largest share of manufacturing demand in 2026 and market estimates pointing to a market measured in billions, which is another way of saying the field has already moved from science project to operating problem.

The beautiful therapy meets the ugly system

A living product does not behave like a tablet. A batch can start as a donor collection, move through activation, editing, expansion, cryopreservation, labeling, shipping, thaw, and infusion, and every one of those steps can break the chain of identity or the chain of custody if the software is thin, the scans are sloppy, or the handoff rules live in someone’s head instead of the system. This is where scale gets moral. A therapy that depends on a precise patient specific route cannot be treated like freight with better branding.

The supply constraint is rarely one thing. Manufacturing slots, viral vector capacity, cold chain handling, site readiness, and scheduling all squeeze together, and the platform has to know which order can actually move, which courier is late, which release result is still pending, and which site can receive the dose before the window closes. One missed handoff can ruin a product that took weeks to make. You feel the waste in your bones when that happens.

I keep thinking about the lab manager at 6:40 in the morning, staring at a freezer log and a patient infusion slot, trying to decide whether a deviation is a paperwork problem or a treatment problem. This is the real theater of cell therapy. The science asks for precision, then the system asks whether precision can survive contact with time zones, couriers, labels, and a release record that has to stand up to audit later.

Delivery strategy is part of the modality

Delivery is not a downstream chore once the cells are made. The route to patient, the receiving site, and the orchestration software sit inside the therapeutic design because autologous and allogeneic models create very different pressure on capacity, scheduling, and traceability. If the platform cannot see manufacturing availability, ship dates, patient identity, and site readiness in one flow, the therapy becomes a set of disconnected events pretending to be a product.

Evidence generation gets awkward in the same place. Commercial reality demands that the same systems carry release data, custody records, label history, and outcome signals without making every change a local exception, because the next question from regulators and clinicians is simple enough and brutal enough: did the thing that arrived really match the thing that was intended, and did it work often enough to justify the whole machine. This is where software stops being support and becomes part of the evidentiary spine.

The companies that will scale cell therapy are the ones treating orchestration, labeling, batch release, and real time traceability as one continuous control surface rather than a pile of integrations held together by hope. Interoperability matters here because manufacturing execution, logistics, lab systems, and EHR adjacent scheduling all speak different dialects, and the therapy fails quietly when those dialects are translated by email and manual reentry instead of a governed data path. A beautiful modality without that path is a story investors like. It is not a therapy you can ship.